PHAT Phathom Pharmaceuticals, Inc.

NASDAQ
$5.08

Phathom Pharmaceuticals, Inc. (PHAT) is expected to report earnings on January 28, 2027, before the market open. The consensus earnings estimate is $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -27.4% since its last earnings release on October 29, 2026.

Phathom Pharmaceuticals Missed Consensus Estimates, Reaffirms Revenue Guidance
Thursday, October 29, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 28
Thursday · 7:00 AM ET
Earnings Whisper
-
vs $0.05
Rev est $97.01M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.